Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (9506)	11/20/2003 11:52:45 AM
From: rkrw	Read Replies (3) \| Respond to of 52153

<<Well, IPO may tell you that.>> Eyetech amends IPO Ophthalmic play Eyetech updated its IPO and now hopes to raise $117-$130 million through the sale of 6.5 million shares at $18-$20. A $19 deal price would raise $123.5 million for the company and value it at $731.1 million. The hoped for post-money valuation is more than double the highest valuation supported by the 2003 IPO window. Cardiovascular in-licensor Myogen (MYOG) had a post-money valuation of $360 million after its IPO on Oct. 29. Eyetech (New York, N.Y.) originally filed on Sept. 12 to raise up to $100 million. On Monday, the company disclosed that its Macugen aptamer met the primary endpoint of significantly reducing the proportion of patients who lost fewer than 15 letters (3 lines) on an eye chart in a Phase II/III trial in age-related macular degeneration. First recent filer I've noticed increase their offering.